A Case Report of Endometrial Carcinoma in a Patient Treated with Tamoxifene and Letrozole for Carcinoma Breast

Title: A Case Report of Endometrial Carcinoma in a Patient Treated with Tamoxifene and Letrozole for Carcinoma Breast

Authors: Avinash Ranjan, Mayank Gautam, S.N. Prasad

DOI: https://dx.doi.org/10.18535/jmscr/v9i3.09

Abstract

The risk of endometrial cancer and breast cancer are increased by higher endogenous estrogen levels. Tamoxifene is a selective estrogen receptor modulater used for treatment and prevention of estrogen receptor positive breast cancer. However it increases the risk of endometrial cancer. Letrozole an aromatase inhibitor reduces breast cancer incidence but their influence on endometrial cancer is uncertain.

Keywords: Endometrial cancer, Tamoxifene, Breast cancer, Letrozole, Aromatase inhibitor.

References

Killackey, M.A.; Hakes, T.B.; Pierce, V.K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 1985, 69, 237–238. [PubMed]
Fisher, B.; Costantino, J.P.; Redmond, C.K.; Fisher, E.R.; Wickerham, D.L.; Cronin, W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994, 86, 527–537. [CrossRef)
Chlebowski, R.T.; Schottinger, J.E.; Shi, J.; Chung, J.; Haque, R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer 2015, 121, 2147–2155. [CrossRef] [PubMed]
Davies, C.; Pan, H.; Godwin, J.; Gray, R.; Arriagada, R.; Raina, V.; Abraham, M.; Medeiros Alencar, V.H.; Badran, A.; Bonfill, X.; et al. Adjuvant Tamoxifen: Longer Against Shorter Collaborative, G. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381, 805–816. [CrossRef]
Lee, M.; Piao, J.; Jeon, M.J. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. Yonsei Med. J. 2020, 61, 317–322. [CrossRef] [PubMed]
Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet 2015, 386, 1341–1352. [CrossRef]

Call For Paper Volume 12 Issue 10 November 2024

The JMSCR is accepting manuscripts for its coming issues to be Publish Volume 12 Issue 11 November 2024 the JMSCR invites authors to submit manuscripts Reporting original medical research, original article, research article, case report, systematic reviews, or educational Innovations for publication for the coming issues that will be released in Volume 12 Issue 11 November 2024. Types of manuscripts suitable for JMSCR include: Medical research, Clinical research Educational Innovation, Brief Report, Reviews on Teaching In keeping with high quality scholarship, Read More.....

https://jmscr.igmpublication.org/ems/index.php/jmscr/about/submissions

If any difficulty you can also submit to: This email address is being protected from spambots. You need JavaScript enabled to view it.

JMSCR Menu

Impact Factor SJIF 2024: 7.892

https://sjifactor.com/passport.php?id=1725

Crossref - DOI

Crossref - DOI Prefix: 10.18535/jmscr

Editorial Policy

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not ..

Frequency of Publication

JMSCR is published as monthly journal with 12 issues per year. Special editions are also planned subjected to the scope and need....

Submission of Articles

Authors are invited to submit their research articles, review papers, Case Report properly formatted as per the author guidelines.........

Search